- Adverum Biotechnologies Inc To discuss the preliminary safety and efficacy data TranscriptFeb 08, 2024
- Adverum Biotechnologies Inc at HC Wainwright Ophthalmology Virtual Conference TranscriptAug 16, 2023
- Adverum Biotechnologies Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Adverum Biotechnologies Inc ADVM-022 Update Call TranscriptJul 22, 2021
- Q4 2020 Adverum Biotechnologies Inc Earnings Call TranscriptMar 01, 2021€107 (+7.00%)Earnings
- Adverum Biotechnologies Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Adverum Biotechnologies Inc Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call TranscriptNov 14, 2020
- Q2 2020 Adverum Biotechnologies Inc Earnings Call TranscriptAug 10, 2020€150 (-3.85%)Earnings
- Adverum Biotechnologies Inc Annual Shareholders Meeting TranscriptJun 23, 2020
- Adverum Biotechnologies Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Q1 2020 Adverum Biotechnologies Inc Earnings Call TranscriptMay 28, 2020€186 (+2.76%)Earnings
- Adverum Biotechnologies Inc to Present New Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD Call TranscriptMay 04, 2020
- Q4 2019 Adverum Biotechnologies Inc Earnings Call TranscriptMar 12, 2020€69 (-16.87%)Earnings
- Adverum Biotechnologies Inc Key Opinion Leader Discussion of OPTIC Phase 1 Clinical Trial Data of ADVM-022 in Wet AMD - Conference Call TranscriptFeb 09, 2020
- Adverum Biotechnologies Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Q3 2019 Adverum Biotechnologies Inc Earnings Call TranscriptNov 07, 2019€72 (+2.13%)Earnings
- Adverum Biotechnologies Inc Key Opinion Leader Discussion of Additional Cohort 1 Data from the Phase 1 OPTIC Trial TranscriptOct 12, 2019
- Adverum Biotechnologies Inc to Review Data Presented at Retina Society 2019 Conference Call TranscriptSep 12, 2019
- Q2 2019 Adverum Biotechnologies Inc Earnings Call TranscriptAug 08, 2019€107.02 (+2.47%)Earnings
Adverum Biotechnologies Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning. My name is Mike Connor, and on behalf of the JPMorgan Health Care Investment Banking team, it's our pleasure to introduce Adverum Biotechnologies. As many of you know, Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a onetime individual injection for the treatment of patients with wet AMD and DME.
Today from the company, we are joined by Laurent Fischer, Chief Executive Officer; Leone Patterson, President; and Aaron Osborne, Chief Medical Officer.
I'll now turn it over to Laurent and the team to walk through the presentation. Laurent?
Thank you, Mike. Good morning, everybody. I'd like to first thank JPMorgan for inviting Adverum to present today. And I hope that everybody is doing well and staying safe at home. These are my forward-looking statements on Slide 2. They are also available in our SEC filing and on the Adverum
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)